XERAVA
Total Payments
$1.0M
Transactions
6,545
Doctors
2,533
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $90,560 | 1,008 | 616 |
| 2023 | $162,275 | 1,772 | 1,027 |
| 2022 | $177,342 | 1,297 | 662 |
| 2021 | $284,845 | 1,362 | 659 |
| 2020 | $324,767 | 1,106 | 678 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $398,500 | 144 | 38.3% |
| Unspecified | $353,284 | 145 | 34.0% |
| Food and Beverage | $195,431 | 6,141 | 18.8% |
| Consulting Fee | $39,916 | 13 | 3.8% |
| Travel and Lodging | $39,046 | 77 | 3.8% |
| Space rental or facility fees (teaching hospital only) | $13,500 | 12 | 1.3% |
| Education | $112.30 | 13 | 0.0% |
Payments by Type
General
$686,506
6,400 transactions
Research
$353,284
145 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Safety and PK Study of IV Eravacycline | Tetraphase Pharmaceuticals, Inc. | $215,088 | 0 |
| In vitro Activity of Eravacycline against Recent Bacterial Isolates Recovered from Patients with Cancer | Tetraphase Pharmaceuticals, Inc. | $71,122 | 0 |
| In vitro susceptibility of Eravacycline against multi-drug resistant enterococci and enterobacteriaceae | Tetraphase Pharmaceuticals, Inc. | $35,860 | 0 |
| Clinical Observation Outcomes Data with Eravacycline (CODE) | Tetraphase Pharmaceuticals, Inc. | $18,713 | 0 |
| In vitro Activity of Eravacycline against staphlococcal biofilms from prosthetic joint infection | Tetraphase Pharmaceuticals, Inc. | $12,501 | 0 |
Top Doctors Receiving Payments for XERAVA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Infectious Disease | The Woodlands, TX | $543.53 | 16 |
| , M.D. , M.P.H | Infectious Disease | Palm Desert, CA | $510.44 | 13 |
| , MD | Infectious Disease | Fairfax, VA | $507.98 | 21 |
| , MD | Infectious Disease | Lexington, KY | $464.66 | 13 |
| , M.D | Specialist | New Smyrna Beach, FL | $461.73 | 25 |
| , MD | Internal Medicine | Claremont, CA | $458.44 | 13 |
| , M.D | Surgery | Tuscaloosa, AL | $447.75 | 8 |
| , MD | Infectious Disease | La Quinta, CA | $446.99 | 10 |
| , M.D | Infectious Disease | Lawrenceville, GA | $435.90 | 20 |
| , D.O | Infectious Disease | Gainesville, GA | $431.90 | 21 |
| , ARNP | Acute Care | Daytona Beach, FL | $431.44 | 23 |
| , M.D | Infectious Disease | Tampa, FL | $428.96 | 16 |
| , M.D | Infectious Disease | Winter Park, FL | $424.21 | 20 |
| , MD | Infectious Disease | Katy, TX | $420.36 | 18 |
| , MD | Infectious Disease | Ashland, KY | $415.08 | 14 |
| , MD | Infectious Disease | Memphis, TN | $412.65 | 20 |
| , MD | Infectious Disease | Reno, NV | $409.13 | 10 |
| , PHYSICIANS ASSISTANT | Medical | Houston, TX | $408.49 | 12 |
| , M.D | Colon & Rectal Surgery | Northport, AL | $400.25 | 6 |
| , MD | Specialist | Fayetteville, AR | $399.62 | 23 |
| , MBBS | Infectious Disease | Birmingham, AL | $399.47 | 10 |
| , M.D | Student in an Organized Health Care Education/Training Program | Macon, GA | $395.65 | 23 |
| , MD | Infectious Disease | Jacksonville, FL | $390.86 | 14 |
| , MD | Student in an Organized Health Care Education/Training Program | Shreveport, LA | $390.51 | 4 |
| , MD | Infectious Disease | Reno, NV | $387.91 | 10 |
Ad
Manufacturing Companies
- La Jolla Pharmaceutical Company $584,263
- Tetraphase Pharmaceuticals, Inc. $364,897
- TETRAPHASE PHARMACEUTICALS, INC. $90,621
- AcelRx Pharmaceuticals, Inc. $8.90
Product Information
- Type Drug
- Total Payments $1.0M
- Total Doctors 2,533
- Transactions 6,545
About XERAVA
XERAVA is a drug associated with $1.0M in payments to 2,533 healthcare providers, recorded across 6,545 transactions in the CMS Open Payments database. The primary manufacturer is La Jolla Pharmaceutical Company.
Payment data is available from 2020 to 2024. In 2024, $90,560 was paid across 1,008 transactions to 616 doctors.
The most common payment nature for XERAVA is "Honoraria" ($398,500, 38.3% of total).
XERAVA is associated with 5 research studies, including "A Safety and PK Study of IV Eravacycline" ($215,088).